scispace - formally typeset
Journal ArticleDOI

Journal club. A systems biologist ponders how disparate ideas can sometimes come together beautifully.

Douglas B. Kell
- 06 Aug 2009 - 
- Vol. 460, Iss: 7256, pp 669
TLDR
PrP can sequester cellular iron in insoluble PrP– ferritin complexes, making it biounavailable, leading to increased iron uptake and an overall excess of iron in brain tissue, and recognition of this could have a colossal effect on thinking and provide new therapeutic options based on iron chelation for these and other syndromes.
Abstract
If X alone and Y alone cannot explain a phenomenon, sometimes together they can. As the late biochemist Henrik Kacser remarked: “To understand the whole you must look at the whole.” Prion diseases, for example, are closely associated with the conformational change of the prion protein PrP from its normal form to an aggregating, autocatalysing, pathologic form, PrP. But clumping prions don’t tell the whole story. Their levels often correlate poorly with disease progression, and it is far from clear how a simple conformational change leads to the holes in brain tissue seen in late-stage disease. It is also clear that poorly liganded iron is highly neurotoxic, mainly because it can spur the production of the highly reactive and toxic hydroxyl radical OH — heavily involved in the progression of many other degenerative diseases and ageing. Neena Singh at Case Western Reserve University in Cleveland, Ohio, and her colleagues have now tied these two disparate threads together. PrP , they found, can sequester cellular iron in insoluble PrP– ferritin complexes, making it biounavailable, leading to increased iron uptake and an overall excess of iron in brain tissue (A. Singh et al., PLoS Pathog. 5, e1000336; 2009). Modified iron metabolism is found in both scrapie and sporadic Creutzfeldt–Jakob disease, and such work stresses that it is not only the total amount of Fe(ii) and Fe(iii) that matters but their speciation. It is yet to be shown whether PrP–ferritin complexes catalyse OH production directly, but if they do, this could account for the massive damage observed. Recognition of this could have a colossal effect on our thinking and provide new therapeutic (and dietary) options based on iron chelation for these and other syndromes. INVERTEBRATE IMMUNITY

read more

Citations
More filters
Journal ArticleDOI

Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples

TL;DR: This work highlights specifically the role of iron metabolism, and the detailed speciation of iron, in chemical and other toxicology, and has significant implications for the use of iron chelating substances as nutritional or therapeutic agents in inhibiting both the progression of these mainly degenerative diseases and the sequelae of both chronic and acute toxin exposure.
Journal ArticleDOI

Brain Iron Homeostasis: From Molecular Mechanisms To Clinical Significance and Therapeutic Opportunities

TL;DR: Recent information on the regulation of iron uptake and utilization in systemic organs and within the complex environment of the brain is reviewed, with particular emphasis on the underlying mechanisms leading to brain iron mis-metabolism in specific neurodegenerative conditions.
Journal ArticleDOI

Nanoscale synchrotron X-ray speciation of iron and calcium compounds in amyloid plaque cores from Alzheimer's disease subjects

TL;DR: In this article, the nanoscale distribution and physicochemical states of biometals, particularly iron, were characterised in isolated amyloid plaque cores from human Alzheimer's disease cases using synchrotron X-ray spectromicroscopy.
Journal ArticleDOI

Mining metabolites: extracting the yeast metabolome from the literature

TL;DR: A novel tool to automatically identify metabolite names in the literature, and associate structures where possible, to define the reported yeast metabolome and, where structure identification fails, has been able to suggest extensions to ChemSpider.
Journal ArticleDOI

Decreased CSF Transferrin in sCJD: A Potential Pre-Mortem Diagnostic Test for Prion Disorders

TL;DR: CSF T-Tf, a new biomarker, when combined with the current biomarker T-tau, is a reliable pre-mortem diagnostic test for sCJD when used alone or in combination with the ‘current’ biomarker total-Tau (T-t Tau).